Choose a language
This webinar will tackle some of the key drivers and benefits to implementing AI for pharma visual inspections to enhance performance, improve accuracy, efficiency and overall quality.
Artificial Intelligence (AI) has triggered a fundamental shift within the innovation paradigm for the pharmaceutical industry and has been implemented in almost every aspect of the value chain, from drug discovery and development to manufacturing.
One application of AI which offers particular value is the realm of visual inspections, which present a challenging step in the packaging process. This is particularly true for products with complex characteristics where manual inspections can sometimes fall short, leading to errors and inconsistencies. AI learning models can optimise the packaging process by detecting minute errors, resulting in fewer rejects, less intervention and a more efficient process overall.
This webinar tackled some of the key drivers and benefits to implementing AI for pharma visual inspections to enhance performance, improve accuracy, efficiency and overall quality.
Project Manager, Special Projects - Stevanato Group
Giacomo Girotto has a MSc in Engineering from the Technical University of Denmark.
Starting his experience in the Pharma business as Site Manager for the headquarter facility of an international industrial services provider, he moved to Stevanato Group to work in the technologies and manufacturing equipment business in 2016.
He started working for SVM, Stevanato Group’s brand specialized in Assembly, Processing and Packaging equipment, and then moved to the Visual Inspection division in 2017, working as Project Manager for special projects, including application of artificial intelligence in the manufacturing process.
Engagement Manager - IQVIA
Aurelio creates topical and forward-looking strategic content relevant to pharma executives worldwide and publishes articles, blogs and white papers on a regular basis.
Aurelio’s predominant focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse on biosimilars, generics and value-added medicines. Moreover, he is involved in numerous projects exploring the interface between healthcare and digital technology.
He is considered a subject matter expert in these areas where he speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects.